Raymond James Downgrades Ascendis Pharma to Outperform, Maintains Price Target to $287
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsDowngradesPrice Target
Raymond James analyst Martin Auster downgrades Ascendis Pharma (NASDAQ:ASND) from Strong Buy to Outperform and maintains the price target from $287 to $287.
Raymond James analyst Martin Auster downgrades Ascendis Pharma (NASDAQ:ASND) from Strong Buy to Outperform and maintains the price target from $287 to $287.